

Form 603
Corporations Act 2001
Section 671B

Notice of initial substantial holder

To Company/registered scheme/notified foreign passport fund name																				
PYC THERAPEUTICS LIMITED																				
ACN/ARSN/APFRN NFPFRN (if applicable)		098 391 961																		
1. Details of substantial holder (1)																				
Name		RA Capital Healthcare Fund GP, LLC, RA Capital Management, L.P., RA Capital Management GP, LLC, Peter Kolchinsky and Rajeev Shah																		
ACN/ARSN/APFRN (if applicable)																				
NFPFRN (if applicable)																				
The holder became a substantial holder on		11/02/2026																		
2. Details of voting power																				
The total number of votes attached to all the voting shares or interests in the company, scheme or fund, that the substantial holder or an associate (2) had a relevant interest (3) in on the date the substantial holder became a substantial holder are as follows:																				
<table border="1" style="width:100%"> <tr> <th>Class of securities (4)</th> <th>Number of securities</th> <th>Person's votes (5)</th> <th>Voting power (6)</th> </tr> <tr> <td>Ordinary</td> <td align="right">83,850,000</td> <td align="right">83,850,000</td> <td align="right">8.99%</td> </tr> </table>				Class of securities (4)	Number of securities	Person's votes (5)	Voting power (6)	Ordinary	83,850,000	83,850,000	8.99%									
Class of securities (4)	Number of securities	Person's votes (5)	Voting power (6)																	
Ordinary	83,850,000	83,850,000	8.99%																	
3. Details of relevant interests																				
The nature of the relevant interest the substantial holder or an associate had in the following voting securities on the date the substantial holder became a substantial holder are as follows:																				
<table border="1" style="width:100%"> <tr> <th>Holder of relevant interest</th> <th>Nature of relevant interest (7)</th> <th>Class and number of securities</th> </tr> <tr> <td>All named relevant interest holders</td> <td>Power to vote and dispose of the securities</td> <td align="right">83,850,000</td> </tr> </table>				Holder of relevant interest	Nature of relevant interest (7)	Class and number of securities	All named relevant interest holders	Power to vote and dispose of the securities	83,850,000											
Holder of relevant interest	Nature of relevant interest (7)	Class and number of securities																		
All named relevant interest holders	Power to vote and dispose of the securities	83,850,000																		
4. Details of present registered holders																				
The persons registered as holders of the securities referred to in paragraph 3 above are as follows:																				
<table border="1" style="width:100%"> <tr> <th>Holder of relevant interest</th> <th>Registered holder of securities</th> <th>Person entitled to be registered as holder (8)</th> <th>Class and number of securities</th> </tr> <tr> <td>All named relevant interest holders</td> <td>Goldman, Sachs & Co.</td> <td>RA Capital Healthcare Fund GP, LLC</td> <td align="right">83,850,000</td> </tr> </table>				Holder of relevant interest	Registered holder of securities	Person entitled to be registered as holder (8)	Class and number of securities	All named relevant interest holders	Goldman, Sachs & Co.	RA Capital Healthcare Fund GP, LLC	83,850,000									
Holder of relevant interest	Registered holder of securities	Person entitled to be registered as holder (8)	Class and number of securities																	
All named relevant interest holders	Goldman, Sachs & Co.	RA Capital Healthcare Fund GP, LLC	83,850,000																	
5. Consideration																				
The consideration paid for each relevant interest referred to in paragraph 3 above, and acquired in the four months prior to the day that the substantial holder became a substantial holder is as follows:																				
<table border="1" style="width:100%"> <tr> <th rowspan="2">Holder of relevant interest</th> <th rowspan="2">Date of acquisition</th> <th colspan="2">Consideration (9)</th> <th rowspan="2">Class and number of securities</th> </tr> <tr> <th>Cash</th> <th>Non-cash</th> </tr> <tr> <td>RA Capital Healthcare Fund GP, LLC,</td> <td>11/02/2026</td> <td align="right">\$125,775,000</td> <td></td> <td align="right">83,850,000</td> </tr> <tr> <td>RA Capital Management, L.P., RA Capital Management GP, LLC, Peter Kolchinsky and Rajeev Shah</td> <td>11/02/2026</td> <td align="center" colspan="2">N/A: no beneficial interest</td> <td align="right">83,850,000</td> </tr> </table>				Holder of relevant interest	Date of acquisition	Consideration (9)		Class and number of securities	Cash	Non-cash	RA Capital Healthcare Fund GP, LLC,	11/02/2026	\$125,775,000		83,850,000	RA Capital Management, L.P., RA Capital Management GP, LLC, Peter Kolchinsky and Rajeev Shah	11/02/2026	N/A: no beneficial interest		83,850,000
Holder of relevant interest	Date of acquisition	Consideration (9)				Class and number of securities														
		Cash	Non-cash																	
RA Capital Healthcare Fund GP, LLC,	11/02/2026	\$125,775,000		83,850,000																
RA Capital Management, L.P., RA Capital Management GP, LLC, Peter Kolchinsky and Rajeev Shah	11/02/2026	N/A: no beneficial interest		83,850,000																

6. Associates

The reasons the persons named in paragraph 3 above are associates of the substantial holder are as follows:

Name and ACN/ARSN/APFRN (if applicable) and NFPFRN (if applicable)	Nature of association

7. Addresses

The addresses of persons named in this form are as follows:


Name	Address
All named relevant interest holders	200 Berkeley Street, 18th Floor, Boston, MA 02116

Signature

print name Craig Randall

capacity General Counsel

sign here



date 13/02/2026

DIRECTIONS

- (1) If there are a number of substantial holders with similar or related relevant interests (eg. A corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 7 of the form.
- (2) See the definition of "associate" in section 9 of the Corporations Act 2001.
- (3) See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001.
- (4) The voting shares of a company constitute one class unless divided into separate classes.
- (5) The total number of votes attached to all the voting shares or interests in the company, scheme or fund (if any) that the person or an associate has a relevant interest in.
- (6) The person's votes divided by the total votes in the body corporate, scheme or fund multiplied by 100.
- (7) Include details of:
 - (a) any relevant agreement or other circumstances by which the relevant interest was acquired. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and
 - (b) any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).See the definition of "relevant agreement" in section 9 of the Corporations Act 2001.
- (8) If the substantial holder is unable to determine the identity of the person (eg. if the relevant interest arises because of an option) write "unknown."
- (9) Details of the consideration must include any and all benefits, money and otherwise, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.